Light Chain Cast Nephropathy Presenting With Asymptomatic Proteinuria

Year 2020, , 22 - 26, 29.01.2020

İlter Bozacı , Erhan Tatar , Funda Taşlı

https://doi.org/10.46310/tjim.648846

Abstract

Kidney disease is a common complication of monoclonal gammopathies including multiple myeloma. Patients with multiple myeloma and other monoclonal gammopathies can present with a variety of kidney manifestations that depend upon the pathologic monoclonal proteins involved and the compartments of the kidney that are targeted. The most common clinical findings include acute or subacute kidney injury, chronic kidney disease (CKD) , albuminuria or nephrotic syndrome and electrolyte abnormalities. The spectrum of kidney impairment ranges from mild to severe acute kidney injury (AKI)  requiring hemodialysis. Most patients presenting with AKI have light chain cast nephropathy. 58 year old female patient was referred to our clinic due to proteinuria. We aimed to represent a light chain cast nephropathy patient presenting with asymptomatic, non-nephrotic range proteinuria and whom were eventually treated with autologous stem cell transplantation. Light chain cast nephropathy should be kept in mind at the differantial diagnosis of patients presenting with asymptomatic non-nephrotic range proteinuria especially whom were treated with anti-proteinuric medications. Kidney biopsy should not be deferred during the diagnostic process.

Keywords

Light Chain, Cast Nephropathy

References

• 1. Gödecke V,Schmidt JJ,Haller H.Diagnosis and Treatment of Kidney Involvement in Plasma Cell Diseases:Renal Involvement in Multiple Myeloma and Monoclonal Gammopathies.Internist Berlin,Jan 2019;60(1):10-22
• 2. Rajkumar SV. 2018 Update on Diagnosis ,Risk Stratification and Management.Am J Hematol,2018 Aug 16;93(8):981-1114
• 3. Fava A,Fulladosa X,Cruzado J M.Treatment of Multiple Myeloma with Renal Involvement:The Nephrologist’s View.Clin Kidney J 2018 Dec;11(6):777-785.
• 4. Yadav P,Cook M,Cockwell P.Current Trends of Renal Impairment in Multiple Myeloma.Kidney Dis(Basel);2016 Mar;1(4):241-57.
• 5. Mohan M,Buros A,Schinke C.Clinical Characteristics and Prognostic Factors in Multiple Myeloma Patients with Light Chain Deposition Disease.Am J Hematol.2017 Aug;92(8):739-745.
• 6. Dimopoulos M A,Sonneveld P,Terpos E.International Myeloma Working Group Recommendations For the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016 May 1;34(13):1544-57.
• 7. Manohar S,Nasr S H,Leung N.Light Chain Cast Nephropathy:Practical Conciderations in the Management of Myeloma Kidney-What We Know and What The Future May Hold.Curr Hematol Malig Rep 2018 Jun;13(3):220-226.
• 8. Finkel K W,Cohen E P.Paraprotein Related Kidney Disease:Evaluation and Treatment of Myeloma Cast Nephropathy.Clin J Am Soc Nephrol,2016 Dec 7;11(12):2273-2279.
• 9. Sathick I J,Drosou M E,Leung N.Myeloma Light Chain Cast Nephropathy,a Review.J Nephrol,2019 Apr;32(2):189-198.
• 10. Gibier JB,Ginemmi V,Buob D.Intratubular Amyloid in Light Chain Cast Nephropathy is a Risk Factor for Systemic Light Chain Amyloidosis.Mod Pathol ,2018 Mar;31(3):452-462.